Samsung Biologics, the South Korean contract drug manufacturer, is making a major move into the fast-growing weight loss drug market with a landmark acquisition worth $1.8 billion.
The company has announced plans to buy out Switzerland-based contract development and manufacturing organisation PolyPeptide for 1.46 billion Swiss francs.
The deal positions Samsung Biologics firmly within the booming peptide production sector, which has surged in prominence alongside global demand for weight loss treatments.
Peptide-based medicines, including the class of drugs behind popular weight loss injections, have become among the most commercially valuable therapeutics in the pharmaceutical industry.
Contract manufacturers with the capability to produce these complex molecules at scale have found themselves in exceptionally high demand from major drugmakers worldwide.
Samsung Biologics has built its reputation as one of Asia’s leading contract manufacturers, producing biologics for some of the world’s largest pharmaceutical companies.
The acquisition of PolyPeptide represents a significant strategic expansion beyond the company’s existing biologics focus, moving deeper into specialised peptide chemistry.
PolyPeptide is a well-established player in the European contract manufacturing landscape, with facilities and expertise specifically tailored to peptide synthesis at commercial scale.
By bringing PolyPeptide under its umbrella, Samsung Biologics gains immediate access to established European manufacturing infrastructure and a client base built over many years.
The transaction, valued at 1.46 billion Swiss francs, underlines the premium that the market is placing on peptide manufacturing capacity at a time of intense competition for supply.
The weight loss drug sector has driven enormous investment across the pharmaceutical supply chain, with manufacturers scrambling to secure reliable production partners capable of meeting surging demand.
Samsung Biologics is betting that ownership of a dedicated peptide CDMO will prove highly lucrative as that demand shows no sign of easing in the near term.
The deal is subject to regulatory approvals and other customary closing conditions before it can be formally completed.